Amdipharm Mercury, Concordia Healthcare deal

Concordia completed its acquisition of fellow generic and pharmaceutical company Amdipharm from private equity firm Cinven for $3.1 billion, including $1.4 billion in debt. The acquisition consists of L800 million ($1.2 billion) in cash, $47.5 million in interest and 8.5 million Concordia shares valued at $230.8 million based on the company’s close of $27.19 on NASDAQ on Oct. 20, the day before the deal closed. The equity represents a 17% ownership in Concordia. Amdipharm is eligible to receive an earn-out payment of up to L144 million ($218.3) million, payable in cash in 4Q16. ...